(Q38703522)

5 September 2017

title

Can advanced-stage ovarian cancer be cured? (English)

1 reference

5 September 2017

1 reference

1

Steven Narod

1 reference

5 September 2017

language of work or name

English

0 references

publication date

20 January 2016

1 reference

Nature Reviews Clinical Oncology

5 September 2017

published in

1 reference

5 September 2017

volume

13

1 reference

5 September 2017

issue

4

1 reference

5 September 2017

page(s)

255-261

1 reference

Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Why have ovarian cancer mortality rates declined? Part I. Incidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Ovarian cancer, version 2.2013.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

A framework for a personalized surgical approach to ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Incorporation of bevacizumab in the primary treatment of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

A phase 3 trial of bevacizumab in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label tr

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Whole-genome characterization of chemoresistant ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Ovarian cancer: sites of recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

Metastatic patterns in adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.224

10.1038/NRCLINONC.2015.224

31 March 2020

Identifiers

DOI

1 reference

5 September 2017

1 reference